Skip to main content
. 2016 Oct 13;18:237. doi: 10.1186/s13075-016-1131-x

Table 1.

Prevalence rates of demographic and clinical characteristics in subgroups of MRI findings

All Subgroup 1: No or few findings Subgroup 2: Mild spinal degeneration Subgroup 3: Moderate/severe spinal degeneration Subgroup 4: Moderate/severe spinal degeneration and mild SIJ findings Subgroup 5: Mild spinal degeneration and moderate/severe SIJ findings P value, significant pair-wise comparisons
(n = 1037) (n = 116) (n = 540) (n = 229) (n = 68) (n = 84)
Age (years), median (IQR) 33 (27–37) 28 (23–33) 32 (26–36) 36 (32–39) 34 (30–37) 29 (25–33) <0.05 for all comparisons except 1 vs 5 and 3 vs 4
Women,% (95 % CI) 54 (51–57) 76 (68–84) 51 (47–55) 40 (33–46) 68 (56–79) 68 (58–78) < 0.01 for 2 vs all and 3 vs all
Regular employment, % (95 % CI) 70 (68–73) 67 (58–76) 71 (67–75) 76 (71–82) 56 (43–68) 67 (56–78) < 0.05 for 2 vs 4 and 3 vs 4
Being overweight (BMI > 25), % (95 % CI) 53 (50–57) 36 (26–46) 51 (47–56) 63 (56–69) 67 (55–79) 53 (41–65) < 0.05 for 1 vs all, 2 vs 3 and 2 vs 4
Previous LBP episode(s), % (95 % CI) 74 (72–77) 58 (48–67) 73 (69–76) 83 (79–88) 81 (71–91) 79 (70–89) < 0.01 for 1 vs all and 2 vs 3
Activity limitation (RMDQ), median (IQR) 57 (39–74) 48 (35–74) 57 (39–74) 57 (39–74) 65 (48–78) 65 (48–78) < 0.05 for 1 vs 4, 1 vs 5, 2 vs 4, 2 vs 5, 3 vs 4 and 3 vs 5
hsCRP, median (IQR) 1 (0–3) 1 (0–3) 1 (0–3) 1 (0–3) 2 (1–5) 3 (0–6) < 0.05 for 1 vs 4, 1 vs 5, 2 vs 4, 2 vs 5, 3 vs 4 and 3 vs 5
HLA-B27-positive, % (95 % CI) 10 (9–12) 12 (6–18) 7 (5–10) 6 (3–9) 12 (4–20) 40 (29–50) < 0.05 for 5 vs all, 1 vs 3 and 2 vs 4

Only variables with a statistically significant group difference (P < 0.05) were included in the above pair-wise comparison, n varies due to missing values

MRI magnetic resonance imaging, IQR interquartile range, CI confidence interval, BMI body mass index, LBP low back pain, RMDQ Roland Morris Disability Questionnaire (calculated as a proportional score (0 % = no activity limitation; 100 % = maximum activity limitation), hsCRP high-sensitivity C-reactive protein, HLA human leukocyte antigen